Theriva Biologics Inc. (TOVX) Tuesday announced positive data from the Phase 1 trial evaluating the safety and tolerability of two intravitreal injections of its investigational oncolytic adenovirus VCN-01 in patients with intraocular retinoblastoma that is refractory to chemotherapy or radiotherapy.
The trial was an investigator sponsored one.
Steven Shallcross, chief executive officer of Theriva Biologics said, "We look forward to building on the encouraging safety profile and antitumor activity, which further supports and informs the design of our proposed Phase 2 clinical trial."
Retinoblastoma is a tumor that originates in the retina and is the most common type of eye cancer in children. VCN-01 is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma.
Shares of Theriva is currently at $0.41, up $4.622 on a volume of 46,927.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.